Verschlechtert die Gabe von rekombinantem humanem Erythropoietin die Prognose von Patienten mit Kopf-Hals-Tumoren unter Radiotherapie?

Wolfgang Jelkmann

Verschlechtert die Gabe von rekombinantem humanem Erythropoietin die Prognose von Patienten mit Kopf-Hals-Tumoren unter Radiotherapie?

Translated title of the contribution: Is recombinant Human Erythropoietin Therapy Disadvantageous in Head and Neck Cancer Patients under Radiotherapy?

Wolfgang Jelkmann

Institute of Physiology

1 Citation (Scopus)

Translated title of the contribution	Is recombinant Human Erythropoietin Therapy Disadvantageous in Head and Neck Cancer Patients under Radiotherapy?
Original language	German
Journal	Strahlentherapie und Onkologie
Volume	180
Issue number	3
Pages (from-to)	179-180
Number of pages	2
ISSN	0179-7158
Publication status	Published - 03.2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

Cite this

@article{b19f3aee3e18460392bc328468e54cfb,

title = "Verschlechtert die Gabe von rekombinantem humanem Erythropoietin die Prognose von Patienten mit Kopf-Hals-Tumoren unter Radiotherapie?",

author = "Wolfgang Jelkmann",

year = "2004",

month = mar,

language = "Deutsch",

volume = "180",

pages = "179--180",

journal = "Strahlentherapie und Onkologie",

issn = "0179-7158",